Peptide education
Thymosin alpha-1
Thymalfasin · Talpha1 · Ta1 · TA-1
Thymosin alpha-1, generically thymalfasin and sold as Zadaxin outside the United States, is a 28-amino-acid immune-modulating peptide, and it breaks the usual pattern on this site: it is an approved drug in dozens of countries with a real label and dosing schedule. The catch is what that approval covers. The evidence is a specific, older record in chronic hepatitis B, a failed modern phase 3 trial in sepsis, scattered and conflicting COVID-era studies, and small vaccine-response signals in selected patients. The clinics and vendors selling it for immune support, long COVID, Lyme, and anti-aging are borrowing the hepatitis record and spending it on conditions that were never established.
Thymosin alpha-1 has a real label and real trials, and every claim lives or dies by its clinical setting: positive in older hepatitis B work, negative in the modern sepsis phase 3, and unresolved nearly everywhere the wellness market uses it.
Overview
Quick answer
Thymosin alpha-1 is not thymosin beta-4 and it is not TB-500. The names sound related because they come from the thymosin family, but alpha-1 is mainly discussed as an immune-modulating thymalfasin product, while thymosin beta-4 and TB-500 are usually discussed around repair, wound healing, and tissue remodeling. Their study history, safety, and regulatory status are different.
What is thymosin alpha-1?
A 28-amino-acid thymic peptide, generically thymalfasin, that tunes immune signaling (dendritic cells, T cells, antigen presentation) rather than killing anything directly. Zadaxin is the branded version approved outside the United States.
Where are the best human data?
Chronic hepatitis B, in an older treatment era: randomized trials reported virologic responses, and the Indonesian Zadaxin label lists 1.6 mg subcutaneously twice weekly for six months. That record is real and it is specific; it does not convert into modern U.S. first-line hepatitis therapy or a general immune claim.
What route and dose patterns are reported in published sources?
Nearly all formal work is subcutaneous. The Zadaxin hepatitis label and the old HBV trials used 1.6 mg twice weekly for six months. Sepsis trials used short hospital courses (twice daily, then daily, over seven days in ETASS; every 12 hours in TESTS), and a COVID pilot used 1.6 mg daily for one week.
What do clinics, forums, and vendors talk about?
Immune support, long COVID, chronic fatigue, Lyme, MCAS, EBV, vaccine response, cancer support, and anti-aging. Forum reports describe fatigue and brain-fog improvements; FTC warning letters document clinics marketing it around COVID prevention. All of that tells you what is being sold, not who benefits.
What is the biggest product issue?
That a purity number is not an injectable product. FDA's compounding briefing raised impurities, aggregates, bioburden, endotoxin, and solubility at the proposed 3 mg/mL concentration, none of which a COA answers. The peptide is not FDA-approved, so U.S. supply is clinic, compounded, or gray-market material without the Zadaxin label's controls.
Why do claims differ by clinical setting?
Because the evidence does. Hepatitis B has positive old trials, sepsis has a large modern phase 3 that missed its mortality endpoint, COVID studies conflict, vaccine work is small and in selected groups, and oncology is exploratory. "It worked somewhere" is not "it works everywhere."
Reported practice
Commonly reported protocol
Clinic and community immune protocols. Community-reported patterns, not verified by controlled human trials and not a use recommendation. Full use-pattern detail
Evidence
Evidence snapshot
Non-U.S. Zadaxin labeling and older randomized trials support a hepatitis-B-specific record, with study schedules such as 1.6 mg subcutaneously twice weekly over months.
Earlier sepsis work gave researchers a reason to keep studying the peptide, but the 2025 TESTS phase 3 trial missed its 28-day all-cause mortality endpoint.
COVID-era human sources include a small open-label randomized pilot, a positive retrospective report, a negative cohort signal, and a null mortality analysis. That mix does not justify a simple treatment or prevention claim.
Influenza and H1N1 vaccine-adjunct studies are notable, especially in elderly or hemodialysis populations, but they are not a broad modern vaccine-enhancement standard.
FDA and FTC materials document immune, COVID, injectable, nasal-spray, and clinic-style claims that extend well beyond the strongest human studies.
Claims
Common claims vs evidence
| Claim | Human evidence | Mechanistic evidence | Anecdotal evidence | Verdict |
|---|---|---|---|---|
| Thymosin alpha-1 boosts the immune system. | Human studies support condition-specific questions such as chronic hepatitis B, sepsis, COVID-era treatment attempts, vaccine response, and oncology combinations. They are not enough for a general "better immunity" claim in otherwise healthy people. | Mechanism papers describe effects on dendritic cells, T-cell signaling, antigen presentation, cytokines, natural killer cell activity, and toll-like receptor pathways. That explains why immune studies exist. | Clinics, wellness marketers, and forum posts often compress that biology into "immune support" or broad immune-tuning language. The claim becomes too broad when it is detached from a named study population. | Plausible immune biology, but the human data are tied to specific conditions and study designs. |
| It helps chronic hepatitis B. | This is the best-supported positive human area. The Indonesian Zadaxin assessment lists chronic hepatitis B as the approved indication, and older randomized studies reported virologic-response signals with subcutaneous thymosin alpha-1 schedules over months. | The immune-modulation rationale fits a chronic viral hepatitis question, but the trial outcomes and label matter more than pathway language. | Wellness marketing often uses the hepatitis record to sell unrelated immune and wellness claims. | The hepatitis B claim can be made for older chronic hepatitis B and Zadaxin contexts. That does not create current U.S. approval language or a general viral-illness use. |
| It reduces sepsis mortality. | The older ETASS trial studied severe sepsis with a short subcutaneous schedule. The later TESTS phase 3 trial is more important now because it missed the 28-day all-cause mortality endpoint. | Sepsis immune dysfunction gives a clear rationale for testing immune modulators. | Sepsis is not a clinic-wellness setting; online personal-use discussion does not answer ICU mortality questions. | Not a general sepsis-benefit claim after the current phase 3 result. |
| It treats or prevents COVID-19. | COVID-era data are scattered and inconsistent: one small open-label randomized pilot, positive retrospective reports, negative or null cohort findings, and a preliminary dialysis-prevention report. | T-cell and innate-immune mechanisms made COVID-era testing a reasonable research question. Mechanism did not turn into a clean clinical answer. | FTC warning letters show clinics and marketers presenting thymosin alpha-1 around COVID prevention, immune support, and peptide therapy. Reddit posts also discuss long COVID, fatigue, and brain fog. | A research and anecdote topic, not an established COVID treatment or prevention use. |
| It improves vaccine response. | Older and smaller human studies reported improved immunogenicity in selected groups such as elderly men and hemodialysis patients receiving influenza or H1N1 vaccination. | Effects on antigen presentation, dendritic cells, and T-cell signaling fit a vaccine-response hypothesis. | Clinic copy sometimes turns that into a broad vaccine-support or immune-support message without matching the study population. | Positive evidence in selected groups, but not a general vaccine-upgrade claim. |
| It helps cancer treatment. | Oncology discussion includes exploratory melanoma work and current registry activity in gastric or gastroesophageal junction adenocarcinoma combinations. That keeps the claim in investigational oncology, not standard cancer therapy. | Immune signaling and antigen-presentation effects explain why researchers test it alongside oncology regimens. | Wellness and clinic pages may list broad cancer-adjacent immune support claims, but those lists are weaker than trial outcome sources. | Oncology-adjacent and investigational, with no broad cancer-treatment conclusion from thymosin alpha-1 sources. |
| It helps Lyme, MCAS, ME/CFS, EBV, hair loss, anti-aging, or general wellness. | Those consumer uses mostly come from clinic, forum, Reddit, online protocol, or vendor discussion. The stronger human material is disease- and trial-specific, so broad wellness claims need to be tied back to the exact condition being discussed. | Immune modulation can make those claims sound biologically reasonable, which is why TA1 shows up around chronic infection, immune-support claims, and long-COVID searches. | FDA and FTC materials document wide online and clinic marketing; Reddit discussion shows why people with long COVID or chronic symptoms search for it. | These are documented search and clinic-use themes, but support for each one depends on condition-specific human data. |
| What can a COA tell you about injectable thymosin alpha-1? | A study can describe a controlled product, and an official label can describe a regulated product. A gray-market vial, compounded injectable, nasal spray, or clinic supply still needs its own quality evidence. | This is a manufacturing and formulation question, not an immune pathway question. | Vendor listings often emphasize purity or identity. FDA's compounding review focused on additional injectable-product issues that a simple purity percentage leaves unresolved. | A COA is only one piece. Identity, impurities, aggregates, sterility, endotoxin, concentration, solubility, storage, and chain of custody all matter. |
Bottom line
Main takeaway
This is a real immune drug in much of the world, with an approved hepatitis B schedule, but it is not FDA-approved and its evidence does not stretch to the wellness uses it is marketed for.
Treat every claim as indication-specific: the Zadaxin label, the HBV trials, the failed sepsis phase 3, the mixed COVID studies, and the clinic vial are separate objects, not one pooled immune-support verdict.
Hepatitis B holds the positive historical evidence, TESTS holds the modern negative phase 3, COVID is inconsistent, vaccine response is small and selected, and oncology is exploratory. Weight them separately.
Identity
What it is
Thymosin alpha-1 is an acetylated 28-amino-acid peptide, generically thymalfasin, originally isolated from thymus tissue. As Zadaxin it is an approved drug in dozens of countries for hepatitis and immune-adjuvant indications, which makes it the rare peptide on this site whose schedule comes from a label rather than forum lore: 1.6 mg subcutaneously twice weekly.
It is an immune organizer, not an antimicrobial. The mechanism work describes dendritic-cell maturation, TLR9 and TLR2 signaling, T-cell effects, and antigen presentation: biology broad enough to justify trials in chronic viral hepatitis, sepsis, COVID, vaccines, and cancer combinations.
The results are a study in setting-dependence. The old hepatitis B trials were positive enough to anchor a label. The 2025 TESTS phase 3 in sepsis missed its 28-day mortality endpoint. COVID-era studies point in different directions. The vaccine-adjunct signals are real but small and confined to elderly and hemodialysis patients.
Keep it separate from thymosin beta-4 and TB-500: same family name, different molecule, different claims, different evidence. And keep the drug separate from the market: U.S. clinics, telehealth programs, nasal sprays, and gray-market vials sell the immune-support story without the label, the trial populations, or the product controls.
How people talk about it online
The online conversation is immune-themed: long COVID, chronic fatigue, Lyme, MCAS, EBV, recurrent infections, vaccine support, cancer support, anti-aging. Reddit threads describe people chasing fatigue and brain-fog relief, sometimes reporting dramatic turnarounds, which captures the demand without establishing the effect.
Clinic and telehealth protocols typically copy the Zadaxin schedule, 1.6 mg twice weekly for 8 to 12 weeks, which makes this the rare case where a community protocol has a real label behind it. What it does not have is the label's indication: borrowing a hepatitis schedule for long COVID is still an untested use with an unverified product.
FDA and FTC warning letters document the marketing end: COVID prevention claims, immune-boosting copy, injectable and nasal-spray products. The warning letters, not the testimonials, are the reliable description of what the market is claiming.
Use context
Routes, doses, and cycle patterns
The best-described disease-specific thymalfasin schedules come from Zadaxin labeling and older hepatitis B trials. Sepsis, COVID, vaccine, and oncology studies are separate research settings with mixed results. Clinic, forum, vendor, and gray-market immune-wellness discussion often borrows the same immune language but lacks clear amounts, schedules, cycle lengths, product controls, or follow-up.
Human studies and product labels
Zadaxin chronic hepatitis B labeling
- Purpose
- Chronic hepatitis B in adults with compensated liver disease and HBV replication
- Context
- Non-U.S. assessment report and product labeling
- Route
- Subcutaneous
- Amount
- 1.6 mg
- Frequency
- Twice weekly
- Duration
- 6 months
This schedule belongs to the Zadaxin chronic hepatitis B product context. It does not describe general wellness, COVID, long COVID, Lyme, MCAS, or anti-aging use.
Chien chronic hepatitis B randomized trial
- Purpose
- Virologic response in chronic hepatitis B
- Context
- Randomized controlled trial
- Route
- Subcutaneous
- Amount
- 1.6 mg
- Frequency
- Twice weekly
- Duration
- 26 weeks or 52 weeks
The trial reported higher complete virologic response at 18 months than untreated control in this older treatment era. That is separate from modern first-line HBV therapy and broad immune-support questions.
Mutchnick chronic hepatitis B phase III trial
- Purpose
- Chronic hepatitis B treatment response
- Context
- Multicenter randomized, double-blind, placebo-controlled phase III trial
- Route
- Subcutaneous
- Amount
- 1.6 mg
- Frequency
- Twice weekly
- Duration
- 6 months
This older placebo-controlled study helps explain why the hepatitis B signal is more substantial than most wellness claims attached to the peptide.
Iino Japanese chronic hepatitis B trial
- Purpose
- Chronic hepatitis B monotherapy
- Context
- Randomized clinical trial
- Route
- Subcutaneous in the thymosin alpha-1 study context
- Amount
- 0.8 mg or 1.6 mg
- Frequency
- Not reported
- Duration
- 24 weeks
This adds another older HBV human study, but the available detail is less complete than the label and Chien trial summaries.
HBV combination study with interferon alfa-2b
- Purpose
- Combination treatment in anti-HBe-positive chronic hepatitis B
- Context
- Small clinical study
- Route
- Subcutaneous
- Amount
- 1.6 mg thymosin alpha-1 plus interferon alfa-2b 10 MIU
- Frequency
- Thymosin alpha-1 twice weekly; interferon alfa-2b three times weekly
- Duration
- 26 weeks of combination therapy, then interferon alone for another 26 weeks
This is a specialized older hepatitis B regimen, not a model for general immune use.
ETASS severe sepsis trial
- Purpose
- Immune and mortality outcomes in severe sepsis
- Context
- Multicenter single-blind randomized trial
- Route
- Subcutaneous
- Amount
- 1.6 mg
- Frequency
- Twice daily for 5 days, then once daily for 2 days
- Duration
- 7 days
This short hospital regimen became part of the sepsis research record, but the later phase 3 result is the more important takeaway.
TESTS sepsis phase 3 trial
- Purpose
- 28-day all-cause mortality in adults with sepsis
- Context
- Multicenter, double-blind, randomized, placebo-controlled phase 3 trial
- Route
- Subcutaneous
- Amount
- Not reported
- Frequency
- Every 12 hours
- Duration
- Not reported
The trial missed the 28-day all-cause mortality endpoint, so the sepsis evidence remains mixed and does not confirm a mortality benefit.
COVID-19 hospitalized-patient pilot
- Purpose
- COVID-19 with hypoxemia and lymphocytopenia
- Context
- Prospective open-label randomized pilot trial
- Route
- Subcutaneous
- Amount
- 1.6 mg
- Frequency
- Daily
- Duration
- 1 week
This pilot described immune-cell recovery signals in a small hospital setting. It is too preliminary to answer COVID treatment or prevention questions.
Vaccine-adjunct studies
- Purpose
- Influenza or H1N1 vaccine immunogenicity in selected groups
- Context
- Older double-blind study and later hemodialysis pilot trial
- Route
- Public summaries do not provide one shared vaccine-adjunct route
- Amount
- Public summaries do not provide one shared vaccine-adjunct amount
- Frequency
- Public summaries do not provide one shared vaccine-adjunct frequency
- Duration
- Public summaries do not provide one shared vaccine-adjunct duration
These studies explain why vaccine-response interest exists, but they do not set a broad vaccine-enhancement standard.
Melanoma phase II study
- Purpose
- Metastatic melanoma adjunctive research
- Context
- Randomized phase II oncology study
- Route
- Not reported
- Amount
- 1.6 mg, 3.2 mg, or 6.4 mg with dacarbazine and with or without interferon alfa
- Frequency
- Not reported
- Duration
- Not reported
Relevant to oncology-adjacent research, but not a broad cancer-treatment claim and not a clinic wellness protocol.
Real-world discussion
Clinic and community immune protocols
- Purpose
- Immune support and infection-adjacent discussion
- Context
- Clinics, telehealth, and community reports
- Route
- Subcutaneous injection
- Amount
- Community and clinic protocols commonly mirror the 1.6 mg twice-weekly schedule of the approved Zadaxin product used outside the United States.
- Frequency
- Twice weekly in most descriptions
- Duration
- Typically 8 to 12 week courses, sometimes longer in clinic immune programs
Thymosin alpha-1 is an approved drug in dozens of countries with label-defined schedules, which makes it unusual on this site: the real-world schedule is borrowed from an actual label rather than forum lore. It is not FDA-approved. Reported as context, not a recommendation.
What varies
- Match the claim to the source: labels give product instructions, trials report endpoints, registries show study intent, FDA or FTC records flag regulatory risk, and forums or vendors show what people encounter or are sold.
- Condition: chronic hepatitis B data do not carry straight into COVID, long COVID, Lyme, MCAS, cancer, or general wellness.
- Route: subcutaneous injection is the formal route in many label and trial sources; nasal-spray marketing does not have the same support here.
- Amount: 1.6 mg appears repeatedly in HBV, sepsis, COVID, and oncology sources, but the meaning changes with population, frequency, duration, and product.
- Product quality: injectable thymosin alpha-1 requires identity, assay, impurities, aggregates, sterility, endotoxin, concentration, solubility, storage, and chain-of-custody review.
Human data
Human evidence
By peptide-market standards the human literature is deep; by drug standards it is uneven. Chronic hepatitis B has the strongest positive record: multiple older randomized trials and a non-U.S. label at 1.6 mg twice weekly for six months. Sepsis has the most rigorous test, the 2025 TESTS phase 3, and it found no reduction in 28-day all-cause mortality. COVID-era publications conflict: a small positive pilot, a positive retrospective report, a negative cohort, a null mortality analysis. Vaccine-adjunct studies showed immunogenicity signals in selected elderly and dialysis populations, and oncology remains exploratory. None of it covers the wellness uses.
Evidence maturity
Thymosin alpha-1 is the rare community peptide with a defined label and schedule: just not in the US.
Isolated from thymus tissue; dendritic-cell and T-cell biology.
Zadaxin approved in dozens of countries for hepatitis and immune-adjuvant use.
Not FDA-approved; clinic and gray-market supply.
Schedules mirror the approved 1.6 mg twice-weekly label.
| Study / evidence area | Population | Design | Product context | Main outcome | Limitations | Weight |
|---|---|---|---|---|---|---|
| Zadaxin / thymalfasin chronic hepatitis B assessment | Adults with compensated chronic hepatitis B and HBV replication | Non-U.S. assessment report and product labeling | Regulated non-U.S. thymalfasin product context | Supports chronic hepatitis B as the approved indication in the Indonesian assessment and gives a label-style 1.6 mg twice-weekly subcutaneous regimen. | This describes a non-U.S. chronic hepatitis B product, not U.S. approval or broad immune, wellness, COVID, Lyme, long-COVID, MCAS, or anti-aging use. | Moderate human data in a specific historical indication |
| Chien chronic hepatitis B trial | Patients with chronic hepatitis B | Randomized controlled trial | Clinical-trial thymosin alpha-1 | Reported higher complete virologic response in thymosin alpha-1 groups than untreated control at 18 months. | Older comparator, older treatment era, and a disease-specific population. | Moderate historical human data |
| Iino chronic hepatitis B trial | Japanese patients with chronic hepatitis B | Randomized clinical trial | Clinical-trial thymosin alpha-1 | Supports an older chronic hepatitis B efficacy and safety signal at 0.8 mg or 1.6 mg over 24 weeks. | Exact endpoint and schedule detail is less complete in the available study summary than in the label-style sources. | Moderate historical human data |
| ETASS severe sepsis trial | Patients with severe sepsis | Multicenter single-blind randomized controlled trial | Hospital research use | Studied a short subcutaneous course and immune/mortality endpoints, helping drive later sepsis research. | Later phase 3 data are more important for a current mortality claim. | Limited to moderate human data |
| TESTS sepsis trial | Adults with sepsis | Multicenter, double-blind, randomized, placebo-controlled phase 3 trial | Hospital research use | Found no clear decrease in 28-day all-cause mortality. | It answers sepsis mortality, not unrelated chronic immune or wellness questions. | Stronger design, non-confirmatory result |
| COVID-19 human studies | Hospitalized, critical-care, or dialysis populations depending on the study | Small randomized pilot plus retrospective and cohort studies | COVID-era hospital or dialysis research use | Published findings conflict: some reports suggested benefit, while others found no mortality benefit or an unfavorable non-recovery signal. | Small size, confounding, open-label design, changing COVID care, and inconsistent populations prevent a clean treatment or prevention claim. | Mixed and weak for broad treatment claims |
| Vaccine-response studies | Elderly men and hemodialysis patients in selected vaccine studies | Older double-blind clinical study and pilot clinical trial | Vaccine-adjunct research use | Reported improved immunogenicity signals in selected groups. | Small or older studies, immunogenicity endpoints, and selected populations; not a broad vaccine-response product claim. | Limited human data |
| Oncology-adjacent sources | Metastatic melanoma study participants and a gastric/GEJ adenocarcinoma registry population | Randomized phase II study plus ClinicalTrials.gov registry context | Combination oncology research | Supports continued oncology-adjacent investigation and an exploratory melanoma signal, not a general cancer-treatment conclusion. | Exploratory, combination-based, and not practice-defining for broad cancer claims. | Exploratory human data |
Cautions
Safety and unknowns
- Formal label and trial settings generally describe tolerability as relatively favorable, with injection-site discomfort and rare rash-like or inflammatory events, while long-term and population uncertainties remain.
- Pregnancy risk, nursing exposure, pediatric safety, drug-interaction questions, and long-term carcinogenicity remain important gaps in the label-style material.
- Immune-modulating products can still be risky for people with autoimmune disease, active malignancy, transplant-related issues, immunosuppressive therapy, uncontrolled infection, or complex inflammatory illness.
- Hospital studies in sepsis or COVID are a poor substitute for home-use safety data in chronic wellness settings.
- The highest everyday risk may be product-related: a mislabeled, contaminated, degraded, over-concentrated, under-concentrated, or poorly reconstituted injectable peptide can create risks that formal trials do not measure.
Product quality
A vial label is only a starting point
FDA's thymosin alpha-1 compounding briefing is specific: identity and purity are only part of the injectable-product quality issue.
FDA discussed missing or inadequate characterization for impurities, aggregates, bioburden, bacterial endotoxins, and solubility, including a proposed 3 mg/mL injectable concentration.
Clinic supply, compounded supply, research-use vials, nasal sprays, and vendor COAs are different from study material or a regulated product.
Identity
The vial must contain thymosin alpha-1 / thymalfasin rather than a different thymosin peptide, fragment, salt mismatch, or unrelated material.
Impurities and aggregates
FDA flagged these as critical because peptide-related impurities and aggregates can change immune risk.
Sterility and bioburden
A subcutaneous injectable product requires microbial control; a purity COA alone leaves sterility unanswered.
Endotoxin
Bacterial endotoxin can produce serious reactions even when identity and assay look acceptable.
Concentration and solubility
FDA discussed solubility concerns for the proposed 3 mg/mL injection, which makes concentration claims more than simple dose math.
Reconstitution, storage, and shipping
Lyophilized peptide handling, diluent choice, cold-chain claims, and post-reconstitution storage all affect what reaches the user.
Mechanism
How it is proposed to work
Thymosin alpha-1 is best described as an immune organizer, not a simple immune booster. It can affect how dendritic cells, T cells, antigen presentation, cytokines, natural killer cell activity, and toll-like receptor signaling behave in certain contexts.
Dendritic-cell maturation and IL-12 signaling are part of the mechanism discussion, which helps explain interest in infections, vaccines, and oncology.
Chronic viral hepatitis, severe infection, vaccine response, and cancer combinations all involve immune recognition or immune dysfunction, so the research spread follows the biology.
Mechanism breadth is also why marketing gets overextended. A molecule can touch many immune pathways without producing reliable clinical benefits across every immune-related condition.
Thymosin alpha-1 is a 28-amino-acid thymic peptide that signals through TLR9 and TLR2 on dendritic cells and promotes T-cell maturation. It is an approved drug (Zadaxin) in dozens of countries for hepatitis and immune-adjuvant indications: which is why its schedule is label-defined rather than community-invented.
FAQ
Common questions
Does thymosin alpha-1 have human evidence?
Yes, but it is condition-specific. Non-U.S. Zadaxin labeling and older chronic hepatitis B randomized trials, sepsis trials, COVID-era studies, vaccine-response studies, and oncology sources each require separate interpretation rather than one broad immune-support conclusion.
Can hepatitis B or sepsis studies be used as wellness evidence?
No. Disease-specific studies and FDA compounding review do not answer broad immune, infection-prevention, long-COVID, Lyme, longevity, or wellness claims without direct evidence for those uses.
What practical details are actually documented?
Disease-specific routes and study-reported schedules are documented for selected settings, along with clinic and forum claims and product-quality concerns. Those details do not add up to a personal protocol.
What do clinics and forums commonly discuss it for?
Common public discussion includes immune support, COVID, long COVID, chronic infections, Lyme, MCAS, ME/CFS, vaccine response, anti-aging, and broad immune-support claims. Those are public and marketing contexts, not demonstrated benefits for those goals.
Details
Technical details
Sources
References
- 1.
FDA. Thymosin Alpha-1 related bulk drug substances, Pharmacy Compounding Advisory Committee meeting 2024.
Accessed 2026-06-09.
Regulatory-quality FDA PCAC material evaluating thymosin alpha-1 related bulk drug substances and proposed compounded uses.
- 2.
PubMed. Efficacy of thymosin alpha1 in patients with chronic hepatitis B: a randomized, controlled trial 1998.
doi:10.1002/hep.510270527 PMID:9581695 Accessed 2026-06-09.
Older randomized controlled trial in chronic hepatitis B.
- 3.
doi:10.1111/j.1365-2893.2005.00633.x PMID:15850471 Accessed 2026-06-09.
Older randomized clinical trial in Japanese patients with chronic hepatitis B.
- 4.
doi:10.1136/bmj-2024-082583 PMID:39814420 Accessed 2026-06-09.
Recent multicenter phase 3 sepsis trial; the reviewed sources say it did not provide clear evidence of reduced 28-day all-cause mortality.
- 5.
ClinicalTrials.gov. ClinicalTrials.gov record for anti-PD-1, thymalfasin, and SOX in cStage III gastric/gastroesophageal junction adenocarcinoma 2026.
NCT06461910 Accessed 2026-06-09.
Trial registry context showing thymalfasin remains under study in combination oncology research.
- 6.
Other. THYMOSIN ALFA 1, INJECTION (THYMALFASIN) assessment report 2024.
Accessed 2026-06-15.
Indonesian BPOM assessment report for Zadaxin / thymalfasin; covers non-US chronic hepatitis B labeling, labeled regimen, identity, pharmacokinetics, and safety.
- 7.
PubMed. Thymosin alpha1 treatment of chronic hepatitis B 1999.
PMID:10607256 Accessed 2026-06-15.
Multicenter placebo-controlled chronic hepatitis B phase III trial.
- 8.
PubMed. Combination thymosin-alpha 1 and interferon-alpha 2b in the treatment of anti-HBe-positive chronic hepatitis B 2002.
PMID:12063993 Accessed 2026-06-15.
Small chronic hepatitis B combination study with interferon alfa-2b.
- 9.
PubMed. The efficacy of thymosin alpha 1 for severe sepsis (ETASS) 2013.
doi:10.1186/cc11932 PMID:23327199 Accessed 2026-06-15.
Older severe sepsis randomized trial used as a regimen anchor before the later TESTS trial.
- 10.
PMID:36056913 Accessed 2026-06-15.
Small open-label randomized COVID-19 pilot trial.
- 11.
PubMed. Efficacy of Thymosin Alpha 1 in the Treatment of COVID-19 2021.
PMID:34408744 Accessed 2026-06-15.
COVID-19 cohort study reporting an unfavorable non-recovery signal.
- 12.
PMID:32442287 Accessed 2026-06-15.
Retrospective COVID-19 study reporting a favorable association in severe disease.
- 13.
PubMed. Thymosin alpha1 use in adult COVID-19 patients 2021.
PMID:33208294 Accessed 2026-06-15.
Critical COVID-19 analysis reporting no mortality association.
- 14.
PubMed. A pilot trial of Thymalfasin (Ta1) to prevent COVID-19 infection and severe sequelae in renal dialysis patients 2023.
PMID:36881981 Accessed 2026-06-15.
Preliminary dialysis COVID-19 prevention report.
- 15.
PubMed. Augmentation of influenza antibody response in elderly men by thymosin alpha one 1989.
PMID:2642497 Accessed 2026-06-15.
Older double-blind placebo-controlled influenza vaccine response study in elderly men.
- 16.
PubMed. Thymosin-alpha 1 (Zadaxin) enhances the immunogenicity of an adjuvanted H1N1 vaccine in hemodialyzed patients 2012.
PMID:22178096 Accessed 2026-06-15.
Pilot H1N1 vaccine immunogenicity trial in hemodialysis patients.
- 17.
PMID:20194853 Accessed 2026-06-15.
Exploratory melanoma phase II source for oncology-adjacent discussion.
- 18.
PubMed. Thymosin alpha1 activates dendritic cells for antifungal Th1 resistance through toll-like receptor signaling 2004.
PMID:14982877 Accessed 2026-06-15.
Mechanism paper on dendritic-cell and toll-like receptor signaling.
- 19.
PubMed. Pharmacokinetics of thymosin alpha1 after subcutaneous injection of three different formulations in healthy volunteers 1999.
PMID:10027483 Accessed 2026-06-15.
Human pharmacokinetic study after subcutaneous administration.
- 20.
FTC. COVID-19 warning letter to Alpha Hormones, Inc. 2020.
Accessed 2026-06-15.
FTC warning letter documenting thymosin alpha-1 immune and COVID-19 marketing claims.
- 21.
FTC. COVID-19 warning letter to The Fuel Stop 2020.
Accessed 2026-06-15.
FTC warning letter documenting clinic-style thymosin alpha-1 peptide therapy and COVID-19 prevention marketing.
- 22.
Reddit. 5 Years Long Covid - Thymosin Alpha 1 Peptide - WOW! 2026.
Accessed 2026-06-15.
Anecdotal Reddit thread documenting online discussion; no efficacy claim.